- Home
- TFSL vs GH Comparison
TFSL vs GH Comparison
Compare TFSL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFSL
- GH
- Stock Information
- Founded
- TFSL 1938
- GH 2011
- Country
- TFSL United States
- GH United States
- Employees
- TFSL N/A
- GH N/A
- Industry
- TFSL Savings Institutions
- GH Medical Specialities
- Sector
- TFSL Finance
- GH Health Care
- Exchange
- TFSL Nasdaq
- GH Nasdaq
- Market Cap
- TFSL N/A
- GH 4.3B
- IPO Year
- TFSL 2007
- GH 2018
- Fundamental
- Price
- TFSL $12.75
- GH $38.75
- Analyst Decision
- TFSL Hold
- GH Strong Buy
- Analyst Count
- TFSL 3
- GH 14
- Target Price
- TFSL $14.33
- GH $39.93
- AVG Volume (30 Days)
- TFSL 275.1K
- GH 1.8M
- Earning Date
- TFSL 01-28-2025
- GH 02-20-2025
- Dividend Yield
- TFSL 9.09%
- GH N/A
- EPS Growth
- TFSL 7.69
- GH N/A
- EPS
- TFSL 0.28
- GH N/A
- Revenue
- TFSL $304,660,000.00
- GH $692,256,000.00
- Revenue This Year
- TFSL N/A
- GH $32.21
- Revenue Next Year
- TFSL $7.19
- GH $16.90
- P/E Ratio
- TFSL $44.64
- GH N/A
- Revenue Growth
- TFSL N/A
- GH 29.20
- 52 Week Low
- TFSL $11.70
- GH $15.81
- 52 Week High
- TFSL $15.00
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- TFSL 48.46
- GH 70.24
- Support Level
- TFSL $12.06
- GH $34.80
- Resistance Level
- TFSL $12.75
- GH $39.29
- Average True Range (ATR)
- TFSL 0.23
- GH 1.78
- MACD
- TFSL 0.03
- GH 0.56
- Stochastic Oscillator
- TFSL 86.25
- GH 94.19
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.